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INTRODUCTION 
Recurrent pregnancy loss is defined as the number of 
consecutive miscarriages which is more than 3 occurred within the 
20th week of gestation and it is a very miserable condition for the 
patient. 
Recurrent pregnancy loss (Recurrent Miscarriage) affects 0.5-
1% of couples. The pathophysiology of Recurrent miscarriage is 
complex. The suggested causes include anatomical, genetic and 
molecular abnormalities, endocrine disorders, thrombophilias and 
antiphospholipid syndrome. In approximately 50% of the cases neither 
of the above can be identified. (Szekeres-Bartho J et al.,2008). 
The pathogenesis of human spontaneous abortion involves a 
complex interaction of several genetic and environmental factors. The 
firm association between increased homocysteine concentration and 
neural tube defects (NTD) has led to the hypothesis that high 
concentrations of homocysteine might be embryotoxic and lead to 
decreased fetal viability.  
There are several genetic polymorphisms that are associated 
with defects in folate- and vitamin B12-dependent homocysteine 
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metabolism. (Henrik ZetterBerg et al.,2002) Homocysteine results 
from the transmethylation of methionine. Its metabolism depends 
primarily on three enzymes and several vitamin cofactors. Genetic 
abnormality in these enzymes or deficiency of these vitamins lead to 
hyperhomocysteinemia (HHCh). HHCh is usually biologically defined 
by a fasting value >15 µmol/L. HHCh belongs among the congenital 
hypercoagulable states and is a long-known vascular disease risk 
factor. The discovery that HHCh may also be responsible for several 
pregnancy complications has only recently been made. Studies in this 
area are still scarce and report on limited numbers of patients.  
It nevertheless appears clear that HHCh is associated with the 
syndromes of repeated miscarriage, pre-eclampsia, placenta abruptio, 
thromboembolic events, neural tube defects, and perhaps with fetal 
death-in-utero and intra-uterine growth retardation.   
The prevention of thromboembolic events during pregnancy by 
anticoagulant treatment is also desirable in these patients.(Aubard Y et 
al.,2000) Folates belong to the vitamin B group and are involved in a 
large number of  biochemical processes, particularly in the metabolism 
of homocysteine. Dietary or genetically determined folate deficiency 
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leads to mild hyperhomocysteinemia, which has been associated with 
various pathologies. 
Any research in this field would prove immense help to patients 
with recurrent miscarriage as well help them in preventing future 
complications not only of pregnancy but also in preventing coronary 
artery disease, dementia, osteoporosis, lack of concentration and 
underachievement for which they are more prone. It is shown by 
studies that women with recurrent miscarriage were more likely to 
have family history of cardiovascular disease (GCS Smith, AM Wood, 
JP Pell,J Hattie) 
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REVIEW OF LITERATURE 
DEFINITION OF RECURRENT MISCARRIAGE 
Recurrent miscarriage (RM), which is also referred to as 
repeated pregnancy loss (RPL) and habitual abortion, is defined as 
three or more consecutive spontaneous miscarriages (ESHRE, 2006). 
The experience of repeated pregnancy loss is physically and 
emotionally traumatic to women who are trying to have children. 
INCIDENCE  
The overall frequency of RM was estimated from 1% to 3% 
(ESHRE, 2006, Christiansen et al., 2008). The exact prevalence of 
RM depends on its definition. To date there is no consensus on the 
definition of RM with regard to the numbers of previous miscarriages 
and the gestational age of RM. The American Society for 
Reproductive Medicine defines the numbers of previous miscarriages 
in RM as two or more whereas Europe Society of Reproduction and 
Embryology defines it as three or more (ASRM, 2008, ESHRE, 2006). 
In some studies only pregnancy losses in the first trimester 
(≤14weeks) were included whereas in other studies pregnancy losses 
in the second trimester (≤24weeks) were also investigated (Franssen et 
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al., 2007, Raffaelli et al., 2009, Tempfer et al., 2006, Garrisi et al., 
2009, Jaslow et al., 2009). In some studies the gestational age of 
repeated miscarriages was not clarified (Zolghadri et al., 2008). 
Therefore, it is possible that different study populations were 
examined in current studies.                                            
 
Proposed Etiologies for Recurrent Spontaneous Pregnancy Loss 
CAUSES INCIDENCE 
Genetic factors 3.5 – 5% 
Anatomic factors 12-16%  
Endocrine factors 17-20% 
Infectious factors 0.5-5%  
Immunologic factors 20-50% 
Thrombotic factors  
 ? 
Others 10%  
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GENETIC FACTORS 
Chromosomal Abnormalities 
  Balanced translocation 
  Inversions and insertions 
  Chromosomal mosaicism 
Single gene defects 
  Delta f 508 mutation 
  Cystic fibrosis 
 
Heritable thrombophilias   
X-linked disorders (result in recurrent abortion of male but not female 
offspring) 
ANATOMIC FACTORS 
Congenital 
¾ Incomplete mullerian fusion or septum resorption 
¾ DES exposure (T shaped uterus) 
¾ Uterine artery anomalies 
¾ Cervical incompetence 
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Acquired 
¾ Cervical incompetence 
¾ Synechiae 
¾ Leiomyomas 
¾ Adenomyosis 
 
ENDOCRINE FACTORS 
¾ Luteal phase insufficiency 
¾ PCOS (including insulin resistance and Hyperandrogenism) 
¾ Other androgen disorders 
¾ Diabetes mellitus 
¾ Thyroid disorders 
¾ Prolactin disorders 
 
INFECTIOUS FACTORS 
¾ Bacterial vaginosis 
¾ Chlamydial infection 
¾ TORCH infections 
¾ Mycoplasma & ureaplasma 
¾ ߚ - hemolytic streptococcus 
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IMMUNOLOGIC FACTORS 
Cellular Mechanisms 
¾ Suppressor cell or factor deficiency 
¾ Alterations in major histo compatibility antigen expression. 
¾ Alterations in cellular immune regulation. 
Humoral Mechanisms 
¾ Antiphospholipid antibodies 
¾ Antithyroid antibodies 
¾ Antisperm antibodies 
¾ Antitoproblast antibodies 
¾ Blocking antibody deficiency 
 
THROMBOTIC FACTORS 
Heritable Thrombophilias 
¾ Single gene defects 
¾ Protein C or S deficiency 
¾ Prothrombin G20210A mutation 
¾ Hyper homocysteinemia 
¾ Factor V leiden mutation 
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¾ Antibody – mediated thrombosis 
¾ (APAS, anti ߚ2G1) 
No. of Losses Risk of recurrence 
1 15% 
2 24% 
3 43% 
4 54% 
 
RECOMMENDATIONS FOR THE TESTING OF COUPLE 
PRESENTING WITH RECURRENT MISCARRIAGE (ESHRE) 
• Basic investigations 
• Obstetric and family history, age, BMI, organic solvents, 
alcohol, mercury, lead, caffeine, hyperthermia, smoking 
• Full blood count (blood sugar level and thyroid function tests) 
• Antiphospholipid antibodies (LAC and aLC) 
• Parental karyotype (after 2 miscarriages) 
• Pelvic ultrasound (SIS) and/or hysterosalpingogram and 
hysteroscopy 
• Laparoscopy in case of inconclusive findings 
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RESEARCH INVESTIGATIONS WITHIN THE CONTEXT OF 
A TRIAL (ESHRE) 
• Feto-placental karyotypes 
• Testing of uterine and/or peripheral blood NK cells 
• Mannan-binding lectin (MBL) level 
• Luteal phase endometrial biopsy 
• Homocysteine/folic acid level 
• Thrombophilia screening 
HOMOCYSTEINE CYCLE 
Homocysteine is a sulfur-containing amino acid, rapidly 
oxidized in plasma to the disulfides homocystine and cysteine 
Circulating homocysteine is derived from dietary methionine. 
Homocysteine, in turn, is metabolized either into cystathione or back 
into methionine.  The latter process involves the enzyme methionine 
synthase. Methionine synthase requires donation of a methyl group 
from 5 methyl tetrahydrofolate to produce methionine, and the enzyme 
methylene tetrahydrofolate reductase (MTHFR) is involved in the 
production of 5 methyl tetrahydrofolate from dietary folate sources 
The MTHFR gene is located on chromosome 1 (1p36.3), and two 
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common alleles, the C677T (thermolabile) allele and the A1298C 
allele, have been described. 
The nutritional supplements folic acid, vitamins B2, B6, and B12 
are all required for proper metabolism of homocysteine.  Therefore, 
their deficiency is associated with acquired elevations in circulating 
homocysteine levels. Although heritable deficiencies in the enzymes 
required for metabolism of homocysteine have been described for the 
pathways leading to cystathione formation and those involved in 
reconversion to methionine, point mutations in MTHFR are 
surprisingly common, and can be associated with 
hyperhomocysteinemia and thrombosis.   
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FACTORS LOWERING HOMOCYSTEINE  
• Downs syndrome 
• Ethanol consumption 
• Pregnancy 
• Contraceptives estrogen therapy 
 
CAUSES OF ELEVATED HOMOCYSTEINE 
• Deficiency of folic acid or vitamins B6/B12 
• Kidney disease 
• Low levels of thyroid hormones (hypothyroidism) 
• Methylenetetrahydrofolate reductase (MTHFR) genetic 
mutations 
• Psoriasis 
• Systemic lupus erythematosus 
• Drugs (folate antagonist, B12, B6 antagonist, niacin Ldopa, 
anticonvulsant) 
• Cystathione synthase gene mutation 
• Smoking, coffee consumption 
• Unknown 
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HOMOCYSTEINE IN NORMAL PREGNANCY 
        The normal concentration of fasting homocysteine is between 5 
and 15µmol/L.  The mean plasma concentration in normal pregnant 
women is 5.4 ± 1.4 which is significantly lower than non pregnant (8.7 
± 1.7) (Bonnette et al).  
  Non 
pregnant 
1 trimester 2 trimester 3 trimester 
Homocysteine 
(µmol/L) 
4.4-10.8 3.34-11 2-26.9 3.2-21.4 
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HYPERHOMOCYSTENEMIA 
 
 Values 
Moderate 15-30 µmol/L 
Intermediate 30-100 µmol/L 
Severe > 100 µmol/L 
 
This table shows the values of homocysteine according 
to the varying degree of severity.  
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PATHOPHYSIOLOGY 
 
Molecular mechanisms of homocysteine-induced cellular 
dysfunction include increased inflammatory cytokine expression, 
altered nitric oxide bioavailability, induction of oxidative stress, 
activation of apoptosis and defective methylation.  
1. Increase endothelial cell tissue plasminogen activator binding 
2. Decrease endothelial antithrombotic activity due to changes in 
thrombomodulin function 
3. Activation of factor 7 a and 5 
4. Increase in fibrinopeptide and prothrombin fragments 1&2 
5. Inhibition of protein C and heparin sulfate 
6. Increase in blood viscosity  
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HOMOCYSTEINE AND PREGNANCY COMPLICATIONS 
RECURRENT MISCARRIAGE 
 Wouters et al. were the first to report the association between 
HHCh and repeated miscarriage. They noted that 14% of patients 
presenting with primary repeated miscarriage had HHCh, while 33% 
of patients with secondary repeated miscarriage (after having had 
normal pregnancies) had HHCh. The principal hypothesis set forth in 
these studies was that of premature damage to the decidual or 
chorionic vessels, disrupting the implantation of the conceptus. 
Quere et al. reported that, in a retrospective review of 100 
patients presenting with a clinical picture of repeated miscarriage, 
12% had HHCh, 20% were homozygotes for the thermolabile 
mutation of MTHFR, and 15% had low levels of folic acid. 
 
PREECLAMPSIA 
The oxidative stress by which Homocysteine produces 
endovascular cell damage have also been imputed in the 
pathophysiology of pre-eclampsia. First, Dekker in 1995 reported that 
17.7% of women with severe pre-eclampsia had early onset had 
HHCh compared with 2% prevalence in the general population. 
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Powers et al. [52] observed in their study that HHCh is 
correlated with maternal blood  concentration of cellular fibronectin, 
both in preeclamptic patients and controls. 
 
INTRAUTRINE GROWTH RETARDATION 
Burke et al. were the first to study the association between 
HHCh and IUGR. Leeda et al reported that 19.2% of patients with an 
antecedent IUGR had HHCH by a methionine challenge test 
performed in the post-partum period. 
 
ABRUPTIO PLACENTAE 
Goddjin-Wessel et al. [54] has reported that 31% of Patients 
developing an Abruptio Placentae have HHCh, compared with 9% in 
the control group. De Vries et al. observed that 26% of the patients 
who had an Abruptio Placentae had HHCh without any associated 
causes. Pre-eclampsia were found to have HHCh 3 months after 
pregnancy . 
 
FETAL DEATH 
Burke et al did however observe a 12% miscarriage rate and 
10% perinatal death rate. Czeizel did not, however, observe a decrease 
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in the frequency of fetal death after supplementation with folic acid 
and multivitamins in a general population.Yet this result does not 
permit the extrapolation that vitamin supplementation will not reduce 
HHCh-associated risk. 
 
NEURAL TUBE DEFECTS 
The association between neural tube defects (NTDs) and  HHCh 
has been reported by several authors . NTDs are not due to a direct 
action of HC, but indirectly to a functional abnormality of methionine 
synthetase. Folic acid deficiency and congenital abnormalities of 
MTHFR can both be responsible for NTDs and for HHCh. The 
association between NTDs and HHCh is thus coincidental, but these 
two pathologies often result from the same cause. 
 
VENOUS THROMBOSIS 
HHCh belongs among the congenital hypercoagulable states, 
so-called thrombophilias, with the same order of magnitude as 
antithrombin III, protein C, and protein S deficiencies, resistance to 
activated protein C (via mutation of the Leiden gene of factor V), and 
mutations of factor II. 
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Den Heijer et al. demonstrated that, in a population of 269 
patients who presented with at least one venous thrombosis before the 
age of 70, 10% had HHCh. 
 
In all predisposing conditions for thrombosis, it is 
recommended to begin prophylactic anticoagulation treatment during 
pregnancy and the post-partum period.  Should we propose a 
thromboprophylaxis to pregnant patients with HHCh? The question 
remains without answer today. 
 
(ODDS RATIO FOR HYPERHOMOCYSTEINEMIA IN PREGNANCY 
COMPLICATIONS  ) 
 
 
 
 
 
 
 Early 
Pregnancy 
Loss 
Still 
Birth Preeclampsia 
Placental 
Abruptions 
Fetal 
Growth 
Restriction 
HOMOCY-
STEINE 
6.3(1.4-
28.4) 
1(0.2-
5.6) 
3.5(1.2-10.1) 2.4(0.4-15.9) N/A 
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METHODS TO MEASURE HOMOCYSTEINE 
Blood samples for homocysteine assay should preferably be 
collected into cooled tubes if delays greater than an hour are expected 
prior to separation of plasma, which should be performed as soon as 
possible after venesection. 
 
Methionine loading tests are not necessary to define 
hyperhomocysteinaemia. Pregnancy ranges for plasma homocysteine 
should be established for each laboratory. Homocysteine is measured 
by enzymatic photometric method. It can also be measured by high-
pressure liquid chromatography. 
 
MANAGEMENT 
Administration of supplemental folic acid in doses between 0.2 and 
15 mg/d can lower plasma homocysteine levels without apparent 
toxicity. On the basis of meta-analysis of 12 clinical studies, all but 1 
of which was a placebo-controlled trial, it has been estimated that a 
25% reduction in homocysteine concentration can be achieved with 
mean supplementation of 0.5 to 5.7 mg of folic acid per day; an 
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additional 7% lowering has been observed after the addition of 
vitamin B12 (0.02 to 1 mg/d; mean, 0.5 mg).  
A recent report of the Food and Nutrition Board of the Institute of 
Medicine has recommended an upper limit of 1 mg/d folic acid on the 
basis of the possibility that higher doses may mask signs of vitamin 
B12 deficiency in some subjects. In overt cobalamin deficiency with 
intermediate and severe hyperhomocysteinemia, vitamin B12 can 
normalize homocysteine concentration in 70% of cases. In an open-
label, uncontrolled study, vitamin B6 at ≤250 mg/d was without effect 
in reducing basal homocysteine levels, but doses of 50 to 250 mg/d 
reduced homocysteine levels after a methionine-loading test by 25%.  
Subsequently, a study that used a randomized, placebo-controlled, 
2x2 factorial design demonstrated that 50 mg of vitamin B6 per day 
independently reduced the post–methionine-loading increase in 
homocysteine levels by 22%. In a placebo-controlled study a 
combination of multiple agents including folic acid (0.65 mg/d), 
vitamin B6 (10 mg/d), and vitamin B12 (0.4 mg/d) was very effective 
in reducing homocysteine levels in patients with moderate or 
intermediate hyperhomocysteinemia. 
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It has been reported, however, that increased vitamin intake from 
food sources (1 mg of folic acid, 12.2 mg of pyridoxine, and 50 µg of 
cyanocobalamin per day) failed to maintain normal homocyst(e)ine 
levels attained previously by vitamin supplementation.  
Other vitamins may also influence plasma homocyst(e)ine levels. 
Daily food intake of 0.6 mg of riboflavin, a vitamin that can function 
as a cofactor for MTHFR results in modest reductions in 
homocysteine (0.475 µmol/L), and pharmacological doses of nicotinic 
acid (3000 mg/d) may cause significant elevations. 
Users of multivitamin supplements in observational studies have 
lower homocysteine levels than nonusers, as well as higher 
concentrations of plasma folic acid and vitamins B6 and B12, The daily 
intake of fortified cereals containing 499 and 650 µg of folic acid per 
serving and the recommended dietary amount (RDA) of other 
vitamins reduced homocysteine by 11% and 14%, respectively. 
Regardless of whether you have an MTHFR mutation in both genes 
or not, the treatment for elevated homocysteine is the same—dietary 
intervention and supplementation with folic acid and vitamins B6 and 
B12. The amount of each of these supplements should be adjusted on 
the basis of the degree of homocysteine elevation, not your genetic 
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status. If you have mutations in both MTHFR genes but have normal 
homocysteine levels, you do not need to be on folic acid or vitamin 
B6or B12 therapy.But some suggest homozygous patients with 
homocysteine value more than 15 mol/L expect normalization within 
2 weeks of treatment with 1-4mg/day folic acid, 10-25 mg /day of 
vitamin B6 400-1000 microgram/day of vitamin B12.Hetrozygous will 
need more than 400microgram of folic acid which will be there in 
most of preconceptional folic acid tablets.    
GENERAL MANAGEMENT 
Established treatment 
Tender loving care (TLC)  
Health advices (diet, coffee, smoking and alcohol) (50% 
improvement)    
 
TREATMENT REQUIRING MORE RCTS 
• Aspirin and/or LMW heparins for women presenting with APS 
or (multiple) inherited thrombophilias         
• Progesterone in women presenting with unexplained early and 
late RM       
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• IVIG in women presenting with unexplained secondary RM or 
late RM         
• Folic acid in women presenting with hyperhomocysteinaemia         
• Immunization with third-party donor leukocyte 
 
TREATMENT OF NO PROVEN BENEFIT 
• Immunization with paternal leukocytes or trophoblast 
membranes         
• Multivitamins supplementation         
 
TREATMENT ASSOCIATED WITH MORE HARM THAN 
BENEFIT 
• Daily corticosteroids during the first half of pregnancy 
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AIMS OF THE STUDY 
1. To analyse the incidence of recurrent pregnancy loss in the 
study population. 
 
2. To estimate the relative risk of recurrent early pregnancy loss 
for elevated total plasma homocysteine concentrations and 
compare the levels with those of healthy controls. 
 
3. To assess response after supplement with folicacid B6 and B12 
for those with elevated  homocysteine and  sample repeated 
after 2 months. 
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STUDY DETAIL 
This study was conducted over a period of 30 months at 
department of Obstetrics and Gynaecology, Govt.R.S.R.M. Lying in 
Hospital attached to STANLEY MEDICAL COLLEGE, Royapuram, 
Chennai. 
STUDY PERIOD  
The period of study was from OCTOBER 2009 – OCTOBER 2011 
STUDY DESIGN 
Prospective case-control study    
Patient selection criteria  
INCLUSION CRITERIA 
Recurrent pregnancy loss with at least two consecutive 
spontaneous early pregnancy losses within 16 weeks of menstrual age.  
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EXCLUSION CRITERIA  
y Serum creatinine greater than 90 μmol/L ,  
y Serum alanine aminotransferase greater than 30 IU/L , 
• Medication that might interfere with homocysteine metabolism 
(like folate antagonist, B12, B6 antagonist, niacin Ldopa, 
anticonvulsant) 
y Ectopic pregnancy 
y Molar pregnancy  
60 Patients attending genetic op and antenatal clinic with recurrent 
miscarriage (>2 pregnancy losses ) were  enrolled in the study as cases 
The control group consisted of women who had delivered at least 
one live born infant and no spontaneous abortions and comparable for 
age, geographical area, and social class. 30 antenatal women from 
antenatal op taken as control. 
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All pregnancies to be confirmed by a positive urinary hCG test or 
ultrasound imaging. 
• Detailed history with pedigree analysis done 
• Fasting Blood sample taken after obtaining consent from the 
patient 
• All patients started on routine folic acids 
• For those with elevated homocysteine B6 and B12 added 
• Pedigree analysis of the patients done detail 
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MATERIAL AND METHODS 
Between 2009 and 2011, 75 women who suffered early 
pregnancy losses, attending our genetic clinic and antenatal OP were 
evaluated clinically and 60 women were enrolled for this study. 
Recurrent Pregnancy Loss was defined as three or more consecutive 
miscarriages within 16 weeks gestation with confirmation by 
biochemical pregnancy test [β-human chorionic gonadotrophin (HCG 
100 IU/l] and/or sonography. Ectopic pregnancies or elective 
terminations of gestations were excluded. 
They were categorized as primary and secondary aborters, 
based on whether they had atleast one pregnancy beyond 16 weeks of 
gestational age. A control group of 30 women with normal menstrual 
history and an obstetric history of uncomplicated pregnancies alone 
was registered. All pregnancies  confirmed by a positive urinary hCG 
test or ultrasound imaging. Detailed history with pedigree analysis 
done. Of the 60 women, 42 experienced 2 abortions, 14  experienced   
3 abortions, 4 experienced  more than 3 abortions. 
The patients and controls did not take any vitamin B 
supplementation or oral contraceptives 6 months  before performing 
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homocysteine test. Fasting EDTA Blood sample was taken after 
obtaining informed consent from the patient at 0800 hours. 
Homocysteine levels were measured after overnight fasting.Women 
were excluded if they had elevated  serum creatinine or SGOT.None 
of the subjects of either the study or the control group had a known 
endocrine dysfunction or suffered from gastrointestinal, hepatobiliary, 
renal or vascular disease. Patients with neurological disorders such as 
epilepsy were also excluded. Before admittance,informed consent was 
obtained from all subjects. 
In four women other investigations revealed abnormalities like 
thyroid dysfunction, gestational diabetes, bicornuate uterus etc. Total 
homocysteine concentration was measured by enzymatic photometric 
method, after centrifugation and storing. Patients were considered 
hyperhomocysteinemic if the measured levels exceeded 95 percentile 
level in healthy controls or lab control values. All patients were started 
on oral folicacid supplementation. For those with elevated 
homocysteine, vitamin B6 and B12 were added. 
Fasting homocysteine measurement was repeated after 2 months 
of management. Data were analysed using conventional statistical 
tools and appropriate software (LaMorte statistical tool for MS excel) 
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where needed. Results are given as Mean, Median, Standard Deviation 
(SD).Odds ratio,95% confidence interval was also  calculated. 
Consequently statistical significance was determined using F-test, 
Pearson Chi square test, Fischer linear test. A p- value <0.05 was 
considered to indicate a statistically significant difference. 
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RESULTS AND ANALYSIS 
The median total fasting homocysteine concentration in the 
study group was 8.59µmol/L and in the control group was 6.43 
µmol/L. The distribution of homocysteine concentrations in the study 
group  is given in Table 1. 
TABLE 1 
GROUP NUMBER MEAN SD RANGE 2 Tailed 
P - Value
Study Group 60 8.59 4.22 3.1-22 0.1161 
Primary Aborters  42 8.79 4.51 3.1-22 0.052 
Secondary 
Aborters 
18 8.13 3.53 3.8-20.2 0.015 
 Control Group 30 6.43 3.06 2.5-19.32  
 
(There was no significant difference between the mean values 
of homocysteine  concentration between the two groups). 
In the study group the effect of parity on homocysteine 
concentration is statistically significant. 
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No correlation was found between age and homocysteine levels 
between the two groups.  
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homocysteine, while only one patient in the control group had 
elevated homocysteine. Subgroup analysis showed, 5 were positive in 
the primary aborters and only one case was positive in the secondary 
aborters group.  
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TABLE 3 
COMPARISON BETWEEN PRIMARY AND SECONDARY 
ABORTERS 
PARAMETER PRIMARY ABORTERS 
SECONDARY 
ABORTERS CONTROL 
Median 7.9 7.55 5.65 
Sd 4.51 3.53 3.06 
Odds Ratio 3.91 1.76 3.22 
95%Ci 
 
0.434   to   
35.417 
 
 
0.1   to   29.073 
 
0.37 -28.07 
 
(Primary aborters are more likely to have HHCh than Secondary 
aborters on comparison of Odds ratio and 95%CI) 
 
On comparison of odds ratio and 95% CI between primary and 
secondary aborters, hyperhomocysteinemia is more likely to occur in 
the primary aborters group.(TABLE 3)This correlated well with other 
studies.Further analysis of the positive patients in the form of serum 
folate,methionine loading ,genetic screening were done in selected 
cases. All seven patients were treated with vitamins B6 and B12 apart 
from routine folic acid supplementation. Fasting homocysteine 
measurement was repeated after 2 months of management. 
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TABLE  4 
 
COMPARISON OF HOMOCYSTEINE LEVELS IN VARIOUS 
STUDIES 
 OUR 
STUDY
NELEN
ET AL 
MARISTELL 
D’VA ET AL 
STEEGERS 
ET AL 
Mediancontrol 5.65 12.6 7.85 6.7 
Sdcontrol 3.06 - 3.31 2.4 
Median Cases 7.69 13.1 19.2 6.9 
Sd Cases 4.22 - 6.14 2.3 
 
(Homocystiene levels in various studies compared with our 
study) 
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TABLE  5 
COMPARISON OF ODDS RATIO BETWEEN VARIOUS 
STUDIES 
PARAMETER OUR STUDY 
NELEN 
ET AL 
QUERE 
ET AL 
STEEGERS 
ETAL 
ODDS RATIO 3.22 3.6 2.6 5.6 
CI 
0.37 -
28.07 
1.3-10.0 0.9-7.7 0.5-57.9 
 
            (Odds ratio of our study correlates with Nelen et al)                 
The odds ratio is the ratio of the odds of an event occurring in 
one group to the odds of it occurring in another group. These groups 
might be men and women, an experimental group and a control group, 
or any other dichotomous classification. An odds ratio greater than 1 
indicates that the condition or event is more likely to occur in the first 
group(usually the control group). And an odds ratio less than 1 
indicates that the condition or event is less likely to occur in the first 
group. Our study has an odds ratio of 3.22.(TABLE 5).Nelen et al and 
Quere et al derived an odds ratio of 3.6 and 2.6 respectively.Steegers 
et al derived an odds ratio of 5.6.Steegers et al included both fasting 
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and methionine loaded homocysteine levels in their study,resulting in 
a higher odds ratio in contrast with our study and those of Nelen et al 
and Quere et al. 
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DISCUSSION 
Multiple mechanisms are said to play a role in the aetiology of 
spontaneous and recurrent abortions. Not only  immunological and 
genetic disorders but also endocrine and psychological factors as well 
as infections or  endometriosis may be responsible for embryo loss 
(Bulletti et al., 1996).Several studies reveal the pathogenetic role  for 
inherited thrombophilia in RPL .These studies delineate the 
pathogenetic role of  various factors like protein C,  protein S and 
antithrombin and the role of inherited gene polymorphism of factor V 
Leiden and A20210G of prothrombin, and also for acquired 
thrombophilia, in particular antiphospholipid syndrome. Of these 
factors moderate hyperhomocysteinemia has also been found to be a 
risk factor for recurrent early pregnancy loss (RPL) (Steegers-
Theunissen et al., 1992a; Wouters et al., 1993; Coumans et al.,1999; 
Del Bianco et al., 2004) and even for first early pregnancy loss (Gris 
et al., 2003).  
 
A recent meta-analysis confirmed an increased risk of 
hyperhomocysteinemia for RPL, defined as  two or more spontaneous 
abortions before 16 weeks of menstrualage (Nelen et al., 2000). As to 
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the possible impact of MTHFRpolymorphism, 677 TT homozygosity 
has been shown to increase the risk in some studies, whereas in others, 
no such effect could be detected; these studies have been reviewed 
elsewhere (Zetterberg,2004). In a recent meta-analysis by Rey et 
al.(2003), this polymorphism was not found to increase the risk for 
RPL.There are several reasons to explain the inconsistency of these 
results.  
 
First, there is no homogeneous definition of RPL (at least two 
or three consecutive spontaneous abortions), as well as of 
hyperhomocysteinemia (fasting or afterload concentrations).Second, 
the possible impact of the fetal MTHFR genotype on the risk of RPL 
has not been investigated in most of  the studies. Recently, Zetterberg 
et al. (2002) emphasized the importance of this parameter, as they 
observed an OR of 14.2(95% confidence interval: 1.78–113) in 
spontaneously aborted embryos presenting with one or more MTHFR 
677T and 1298C alleles when compared with the wild-type (677CC 
and 1298AA) genotype. 
 
Thus the risk could even be higher when both the mother and 
her fetus are homozygous,As an example, the interference of a 
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transcobalamin (TC) polymorphism,TC C776G, which influences 
homocysteine metabolism has been investigated (Zetterberg et al., 
2003). TC is a vitamin B12-binding protein and plays a role in the 
transport and bioavailability of this vitamin. Patients with a 
heterozygous or homozygous TC 776 mutation have lower serum TC 
concentration and a tendency toward a higher homocysteine 
concentration(Namour et al., 2001).  
 
Genotype analysis in fetal tissuesfrom 76 spontaneous 
abortions, most of them occurring earlier than week 12, showed that 
embryos presenting with a combined MTHFR 677TT and TC 776CG 
or TC 776GG genotype had an increased risk for RPL when compared 
with embryos that had only one of these mutated genotypes 
(Zetterberg et al., 2003).Fourth, as suggested by the preceding 
observation, etiologies other than folate deficiency or MTHFR 
polymorphism may lead to hyperhomocysteinemia and subsequent 
pregnancy loss.  
 
The association between RPL and vitamin B12 has been 
illustrated by two case reports concerning a 38 year-old woman with 
four episodes of early spontaneous abortion vitamin B12 deficiency 
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and bone marrow megaloblastosis (Candito et al., 2003), and a 36year-
old patient with documented familial and personal history of Addison–
Biermer disease, who had experienced 12 episodes of spontaneous 
abortion in the absence of any other known causes of RPL (Gueant et 
al., 2004). 
Despite several pathophysiological hypotheses including 
impaired cell proliferation, increased oxidative stress, 
apoptosis,reduced extra-embryonic ascular development and 
hypomethylation(Zetterberg, 2004; Latacha and Rosenquist, 2005), it 
is not clear whether hyperhomocysteinemia is causally related to RPL 
or whether it is only a marker of the increased risk of RPL. Actually, 
lowering homocysteine concentration byB-vitamin supplementation 
,that has been shown to have a positive effect in several case reports 
and in our  series also, with spontaneous pregnancies occurring after a 
few months of treatment in patients who had previously experienced 
between 4 and 12 early spontaneous abortions (Quere et al., 1998, 
2001; Candito et al.,2003; Gueant et al., 2004). 
 
There is evidence in the literature that some miscarriages result 
from elevated levels of homocysteine factors present in the sera. 
Increasing evidences are available for the relationship between 
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hyperhomocysteinemia  and MTHFR C677T gene polymorphism and 
unexplained recurrent pregnancy loss. Several reports, in 
fact,described an association between early RPL and HHCh and/or 
MTHFR C677T gene polymorphism [2,3,26,27]. A different point of 
view on the association between hyperhomocysteinemia  and RPL has 
been reported only by Makino et al. [28]. 
 In the present study we evaluated  homocysteinemia in women 
showing RPL. In our study out of 60 cases with RPL 7 cases had 
hyperhomocysteinemia which is not statistically significant. 
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TABLE 1 
STUDY 
CASES WITH 
HYPERHOMO-
CYSTENEMIA 
CONTROLS 
WITH 
HYPERHOMO-
CYSTENEMIA 
P-
VALUE CORRELATION
Our 
study 
6/60 1/30 0.26 No Statistical  
Significance 
Quere et 
al 
12/100 5/100 0.07 No Statistical 
Significance 
Nelen et 
al 
19/123 5/104 0.09 No Statistical 
Significance 
Wouters 
et al 
22/180 3/46 0.27 No Statistical 
Significance
 
(The women with RPL show non significant higher mean 
homocysteine concentrations than controls, correlating with other 
studies). 
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With regards to subgroup analysis.our study showing that  
disturbed homocysteine metabolism may have a greater effect in 
primary aborters than in secondary aborters, suggests that, in primary 
aborters the disturbances are permanent. That could be because of an 
intrinsic metabolic disorder, rather than environment. This contrasted 
with previous reports that showed increased incidence of 
hyperhomocysteinemia in parous women compared with women who 
had primary recurrent early pregnancy loss. Since our study was 
limited to fasting homocysteine levels measurement alone, Further 
detailed investigations of both the groups like may enlighten the 
reasons for this discrepancy. 
 A possible cause of hyperhomocysteinemia in these 7 patients 
will be diminished remethylation induced by decreased concentration 
of active folate,B12,or enzymes involved in remethylation.On 
analyzing after folate and B vitamin complex supplementation ,four  
showed reduced values. This results correlate with other studies as 
discussed below. Meta-analysis of individual data on 1114 people in 
12 randomised controlled trials assessed the effects of folic acid-based 
supplements on blood homocysteine concentrations. Multivariate 
regression analysis was used to determine the effects on homocysteine 
concentration of different doses of folic acid and of the addition of 
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vitamin B12 or B6. The results showed that the proportional and 
absolute reductions in blood homocysteine produced by folic acid 
supplements were greater at higher pre-treatment blood homocysteine 
concentrations (p<0.001) and at lower pre-treatment blood folate 
concentrations (p<0.001). After standardisation to pre-treatment blood 
concentrations of homocysteine of 12 micromol/L and of folate of 12 
nmol/L (approximate average concentrations for Western 
populations), dietary folic acid reduced blood homocysteine 
concentrations by 25 percent (95% confidence interval 23%-28%; 
p<0.001), with similar effects in the range of 0.5-5 mg folic acid daily. 
Vitamin B12 (mean 0.5 mg daily) produced an additional 7 percent 
(3%-10%) reduction in blood homocysteine. Vitamin B6 (mean 16.5 
mg daily) did not have a significant additional effect. In conclusion, 
typically in Western populations, daily supplementation with both 0.5-
5 mg folic acid and about 0.5 mg vitamin B12 would be expected to 
reduce blood homocysteine concentrations by about a quarter to a 
third (for example, from about 12 micromol/L to 8-9 micromol/L.( 
Homocysteine Lowering Trialists’ Collaboration).T Am J Clin Nutr 
2005;82:806 –12. F4.There are studies regarding  the beneficial effect 
of folic acid supplemenataion in women with preeclampsia/eclampsia 
and hyperhomocystenemia in lowering homocysteine levels(Seema 
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Bibi Qureshi et al,Leeda et al)F2. The prospective cohort study by 
Linda Dodds et al has confirmed strong association between increased 
homocysteine levels in early pregnancy and pregnancy loss and the 
development of preeclampsia, but it could not establish whether  
supplemental folic acid will reduce the risk of pregnancy loss or 
preeclampsia, as a consequence of a reduction in total homocysteine 
levels.(F3). Large intervention trials as well as prospective studies 
measuring tHcy and folate status before and during pregnancy are 
needed to establish the role of these and related factors as predictors or 
etiologic factors of adverse pregnancy outcomes. 
Regardless of whether you have an MTHFR mutation in both 
genes or not, the treatment for elevated homocysteine is the same—
dietary intervention and supplementation with folic acid and vitamins 
B6 and B12. The amount of each of these supplements should be 
adjusted on the basis of the degree of homocysteine elevation, not 
your genetic status. If you have mutations in both MTHFR genes but 
have normal homocysteine levels, you do not need to be on folic acid 
or vitamin B6or B12 therapy.  
Although folate deficiency is one of the factors that may lead to 
alterations in DNA synthesis and chromosome structure in rapidly 
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dividing cells (e.g. heritable folate-sensitive fragile site in human 
autosomal chromosome 1p21.3; Baker and Sutherland, 1991),and the 
serum concentration is a sensitive indicator of the folate available for 
replicating cells (Neiger et al., 1993), Abir et al. found the mean 
serum concentration of folic acid to be similar in so called ‘high risk 
sera’ from women with at least two abortions and in control sera from 
women after a normal pregnancy or during a normal second trimester 
of gestation.Several studies on the relationship of the vitamin B 
complex,particularly of folate, to spontaneous abortion have been 
published, but available data with regard to recurrent miscarriage are 
rare. 
The question of whether to add anticoagulant treatment to 
vitamin supplementation is a reasonable one. Prescribing 
anticoagulant therapy is recommended in patients with.a congenital 
hypercoagulable state when this can be identified.  
This prophylaxis consists of treatment by heparin during 
pregnancy and delivery, and during the post-partum However, in 
contrast to the congenital hypercoagulable states, in 
hyperhomocysteinemia we have treatment options capable of 
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normalizing homocysteine levels available to us, in the great majority 
of cases. 
One may thus ponder whether it is useful to give anticoagulant 
treatment throughout pregnancy in a patient whose homocysteine 
levels have been normalized with vitamin supplementation. It will not 
be possible to answer this question until it is known whether vitamin 
supplementation reduces the thrombotic risk in hyperhomocysteinemia 
patients to normal. Such information could only be obtained by a 
multicenter trial.                                 
Many unknowns remain regarding the impact of  
hyperhomocysteinemia on pregnancy and the optimal manner in 
which to manage this condition during pregnancy. Large-scale case–
control studies are needed to clearly define the disease states linked to 
hyperhomocysteinemia. Therapeutic trials are also necessary to study 
the impact of vitamin supplementation and the best manner to 
administer it. 
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SUMMARY 
 
1. Our study has an incidence of recurrent pregnancy loss of 1% in 
RSRM lying hospital. 
2. The study of our 60 RPL cases showed 6 patients with 
hyperhomocysteinemia which has a 10% rate of occurrence.  
3. Our odds ratio with 3.22 indicates that hyperhomocysteinemia 
has an increased rate of occurrence among the people with RPL 
with correlates well with other studies. 
4. Therapeutic normalization of homocysteine in supplementation 
with folic acid B6,B12 in 4 out of 7 indicates the management 
options that can be tried.  
5. Our study indicates that there is no correlation of age with 
hyperhomocysteinemia. 
6. Primary aborters have a higher incidence of 
hyperhomocysteinemia when compared with secondary 
aborters.  
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CONCLUSION 
 
Recent studies on recurrent early pregnancy loss and 
hyperhomocysteinemia suggested a positive association between the 
two.In the present study elevated fasting homocysteine concentrations 
were associated with higher odds ratio in women with 2 or more early 
pregnancy losses. The level showed no significant difference in 
ages.In primary aborters disturbed homocysteine metabolism seemed 
to have a greater effect than secondary aborters in our study indicating 
that intrinsic metabolic disorder rather than environment as a cause of 
homocysteinemia. 
In animal studies folic acid supplementation seemed to improve 
survival of fetuses during early gestations and increases the number of 
living fetuses.In our study also folic acid supplementation along with 
B12 and B6 has an effect on lowering the homocysteinebut the still 
more studies are needed to conclude the effect of folic acid B6,B12 on 
pregnancy outcome.Still more intervention trials as well as 
prospective studies measuring folate and tHcy status before and during 
pregnancy are needed to establish the role of folic acid B6 and B12 
either as  predictors or etiologic factors for recurrent pregnancy losses. 
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We therefore believe that women with hyperhomocysteinemia 
should be identified earlier. The folic acid-vitamin B6,B12 
combination, a nonteratogenic treatment, should be tried. As 
suggested by our case report, therapeutic normalization of 
hyperhomocysteinemia might lead to metabolic restoration, which 
may favor a successful pregnancy outcome. 
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PROFORMA 
 
NAME 
AGE 
IP/OP NO 
ADDRESS 
TELEPHONE NO 
 
MENSTURAL H/O 
• MENARCHY 
• CYCLES REGULAR/IRREGULAR 
• DURATION 
• LMP 
 
MARITAL H/O 
• AGE AT MARRIAGE 
• CONSAGNUITY      
                                 
OBSTETRIC H/O 
• YEARS AFTER MARRIAGE 
• NATURAL/ASSISTED 
• ANTENATAL PERIOD 
• 1ST TRIMESTER 
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• 2ND TRIMESTER 
• 3RD TRIMESTER 
• PEDIGREE     
• PERI CONCEPTIONAL EXPOSURE 
• ILLNESS(FEVER,JAUNDICE) 
• MEDICATION 
• EXPOSURE 
 
FAMILY H/O 
• ABORTION,INFERTILITY,BIRTH  
• DEFECTS,MENTAL RETARDATION 
 
RESIDENCE H/O 
• (FACTORY,TANNERY,POLLUTED 
• WATER,RADIATION,BURNING) 
• OCCUPATION H/O 
 
GENERAL EXAMINATION    
• WIFE HUSBAND 
• VITALS 
• OBSTETRIC EXAMINATION 
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INVESTIGATIONS 
• Hb  
• BLOOD UREA 
• BLOOD SUGAR 
• SERUM CREATINE 
• HIV/VDRL 
• HbSAg  
• CERVICAL SWAB 
• HOMOCYSTEINE 
• USG  
• LFT 
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ABBREVIATION 
RPL  - Recurrent Pregnancy Loss 
HHCH - Hyperhomocysteinemia 
NTD  - Neutral tube Defect 
RM  - Recurrent Miscarriage 
PCOS - Polycystic Ovarian Syndrome 
A PAS - Antiphospholipid antibody syndrome 
MTHFR - Methylene tetrahydro folate Reductase 
LAC  - Lupus Anticoagulant 
SIS  - Saline Infusion Sonography 
TLC  - Tender Loving Care 
HCG  - Human Chronic Gonadotrophin 
SD  - Standard Deviation 
IUD  - Intra Utrine Death 
TC  - Transcobalamin 
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 MASTER CHART 
SL. 
NO NAME AGE 
REG 
NO. 
OBSTETRIC 
CODE 
GESTATIONAL 
AGE LMP EDD USG 
ASSOCIATED 
COMPLICATIONS 
HOMOCYSTEINE 
VALUES 
1 Mrs vasantha 26 15431 G4A3 11  weeks 2 days 8/6/11 15/3/12   8.6 
2 Mrs subanthini 21 12341 G4A3 10  weeks 3 days 12/3/11 19/12/12   3.1 
3 Mrs muniyamal 28 12309 G4A3 12  weeks 2 days 16/4/11 23/1/12   4 
4 Mrs vasanthi 23 13891 G3A2 10  weeks 3 days 2/6/11 9/3/12   6.1 
5 Mrs selvi 24 15432 G5A4 11  weeks 4 days 12/2/11 19/11/11   7.1 
6 Mrs baby 20 61/10 G3A2 12  weeks 3 days 21/8/10 28/5/11 MISSED ABORTION  5.8 
7 Mrs nithya 26 14365 G4A3 10  weeks 2 days 25/8/10 1/6/11   4 
8 Mrs ramani 25 1752 G3A2 11  weeks 4 days 15/2/11 22/11/11 BICORNUATE UTERUS  6.9 
9 Mrs janaki 24 1583 G3A2 12  weeks 2 days 16/6/11 23/3/12   6 
10 Mrs karolin 26 1764 G3A2 10  weeks 5 days 18/4/11 25/1/12  HYPOTHYROID 8 
11 Mrs kameshwari 26 1930 G5A4 13  weeks 5 days 15/6/11 22/3/12 MISSED ABORTION  6.8 
12 Mrs tasleema 23 1783 G3A2 12  weeks 2 days 6/8/10 13/5/11   7.5 
13 Mrs Naomi 24 104/10 G5A4 11  weeks 4 days 6/12/10 13/9/11  GDM 6.3 
14 Mrs poongodi 36 96/10 G3A2 10  weeks 2 days 26/6/10 2/4/11   8.4 
15 Mrs revathy 24 77/10 G3A2 13  weeks 3 days 5/5/10 12/2/11   3.4 
16 Mrs jeyanthi 23 100/10 G3A2 12  weeks 2 days 2/11/10 9/8/11   22 
17 Mrs karpagavalli 24 14501 G3A2 10  weeks 2 days 5/4/11 12/1/12   20 
18 Mrs ramya 20 10/10 G4A3 11  weeks 3 days 7/7/10 14/4/11   19.32 
19 Mrs jegadha 32 1583 G5P1L1A3 13  weeks 1 day 3/6/10 10/3/11 IUD  20.2 
20 Mrs vani 23 1892 G3A2 12  weeks 6 days 4/3/11 11/12/11   4.6 
21 Mrs chellamal 40 14761 G3A2 10  weeks 3 days 18/4/11 25/1/12 MISSED ABORTION HYPOTHYROID 8.5 
22 Mrs allirani 35 29/10 G6P2A3 11  weeks 2 days 4/2/10 11/11/11   4.5 
23 Mrs maheshwari 28 1820 G4P1A2L1 12  weeks 5 days 16/8/11 23/5/12   6.7 
24 Mrs thangamaheshwari 26 25/11 G3A2 13  weeks 3 days 15/12/10 22/9/11   4.3 
25 Mrs muthulakshmi 27 26/11 G4P1A2 14  weeks 1 day 12/11/11 19/1/12 MISSED ABORTION  8.3 
26 Mrs rameshwari 24 17832 G3A2 10  weeks 4 days 18/2/11 27/11/11   7.5 
27 Mrs latha 23 1920 G3A2 12  weeks 2 days 12/3/11 19/12/11  HYPOTHYROID 8.3 
28 Mrs Rekha Malaiappan 22 3482 G3A2 10  weeks 1 days 14/4/11 21/1/12   7.5 
29 Mrs kameshwari 26 4192 G4A3 13  weeks 3 days 25/4/11 1/1/12   5.4 
 
 30 Mrs valliammal 23 3418 G3A2 10  weeks 4 days 12/6/11 19/3/12 MISSED ABORTION  6.8 
31 Mrs Halima 24 2891 G4A3 14  weeks 2 days 6/5/11 13/2/12   6.4 
32 Mrs kalaiselvi 24 14526 G4P1L1A2 12  weeks 1 day 17/7/11 24/4/12   5.6 
33 Mrs saritha 26 16/10 G3A2 14  weeks 3 days 20/5/10 27/2/11  GDM 8.6 
34 Mrs lakshmi 23 5643 G3A2 13  weeks 5 days 15/6/11 22/3/12   19.32 
35 Mrs deivanayagi 36 81/10 G4P1L1A2 12  weeks 2 days 25/2/10 2/12/10   7.5 
36 Mrs selvi 26 5632 G5P2L2A2 10  weeks 3 days 15/7/11 22/4/12   8.6 
37 Mrs aruna 23 7645 G4P1A2 13  weeks 4 days 16/5/11 23/2/12   5.8 
38 Mrs mathiyalagi 24 3421 G3A2 12  weeks 3 days 11/1/11 18/10/11   7.8 
39 Mrs surya 27 9821 G4P1L1A2 10  weeks 1 day 22/5/11 29/2/12   3.89 
40 Mrs suseela 25 4501 G4P1L1A2 13  weeks 4 days 12/8/11 19/5/12  GDM 8.6 
41 Mrs nithya 24 5621 G3A2 14  weeks 2 days 14/8/11 21/5/12   10.4 
42 Mrs shamim nisha 24 2091 G4P1L1A2 12 weeks 3 days 5/3/11 12/12/11 BELIGHTED OVUM  11.4 
43 Mrs tamil malar 23 3210 G7P4L2A2 13  weeks 2 days 14/3/11 21/12/11   6.7 
44 Mrs aparna 22 2150 G4P1L1A2 10  weeks 1 day 16/3/11 23/12/11  HYPOTHYROID 7.4 
45 Mrs radhika 25 2317 G3A2 13  weeks 6/8/11 13/5/12 MISSED ABORTION  18.32 
46 Mrs anitha 23 27/10 G4A3 12  weeks 20/9/10 27/6/11   8.6 
47 Mrs vatsala 26 33/10 G4P1L1A2 10  weeks 3 days 7/10/10 14/7/11   9.8 
48 Mrs nagavalli 22 53/10 G3A2 12  weeks 2 days 5/1/10 12/10/10   8.62 
49 Mrs ramya 21 10/10 G3A2 13  weeks 7/7/10 14/4/11   10.75 
50 Mrs nishanthi 25 2310 G5P1L1A3 10  weeks 4 days 5/5/10 12/2/11   8.67 
51 Mrs deviragavan 38 9/10 G4P1L1A2 13  weeks 2 days 13/7/10 20/4/11   7.1 
52 Mrs sulekha sudhakar 22 63/10 G3A2 12  weeks 5 days 7/7/10 14/4/11 BELIGHTED OVUM  8.6 
53 Mrs subulakshmi 23 64/10 G5P1L1A3 14  weeks 3 days 9/1/10 16/10/10  OVERT DIABETIC 6.5 
54 Mrs bhavani 29 29/10 G3A2 10  weeks 1/2/10 8/11/10   8.4 
55 Mrs Baby Tthulasidas 21 83/10 G3A2 13  weeks 3 days 19/6/10 26/4/11   8.6 
56 Mrs shobana 20 84/10 G3A2 12  weeks 2 days 23/8/10 30/5/11   11.5 
57 Mrs anjalai 23 92/10 G3A2 14  weeks 1 days 3/8/11 10/5/12   9.2 
58 Mrs shyamala 22 103/10 G4A3 10  weeks 3 days 12/10/10 19/7/11   6.8 
59 Mrs sheela 27 15621 G4P1A2 10  weeks 2/5/11 9/2/12 MISSED ABORTION  8.7 
60 Mrs gomathi 26 11983 G7P3A4 12 weeks 5 days 3/6/11 10/3/12   7.6 
 VALUES FOR CONTROL 
S.NO. NAME AGE REG NO 
OBSTETRIC 
CODE LMP EDD 
GESTATIONAL 
AGE USG 
ASSOCIATED 
COMPLICATIONS 
HOMOCYSTEINE 
VALUE 
1 Devi 25  G3P2L2 12/5/11 19/2/12 14 weeks 2 days   4.5 
2 Selvi 23 25527 G2P1L1 23/5/11 30/2/12 14 weeks 1 day   3.6 
3 Renu 22 25907 G2P2L2 2/7/11 9/4/12 13 weeks 3 days   4.6 
4 Vinodhini 24 25333 G2P2L2 26/6/11 2/4/12 14 weeks 2 days   5.4 
5 Mallika 23 25284 G2P2L2 24/7/11 31/4/12 14 weeks 3 days MISSED ABORTION  6.7 
6 Lakshmi 24 24832 G3P2L2 23/8/11 30/5/12 15 weeks 2 days   8.6 
7 Usha 25 22179 G3P2L2 17/8/11 24/5/12 12 weeks 3 days   8.4 
8 Kalaivani 22 20377 G2P2L2 19/7/11 26/4/12 14 weeks 3 days   6.8 
9 Banupriya 23 23971 G2P2L2 26/7/11 2/5/12 15 weeks 2 days   7.8 
10 Dhinakari 24 23964 G2P2L2 31/8/11 7/6/12 15 weeks 4 days   3.5 
11 Selvi 23 24688 G2P2L2 26/7/11 2/5/12 13 weeks 2 days   2.5 
12 Nirmala 22 24690 G2P2L2 18/6/11 25/3/12 14 weeks 5 days   4.6 
13 Umamaheshwari 25 13525 G2P1L1 10/7/11 17/4/12 12 weeks MISSED ABORTION  19.32 
14 Revathy 21 24586 G2P2L2 3/7/11 10/4/12 13 weeks 3 days   7.8 
15 Anjali 22 24357 G2P2L2 16/8/11 25/5/12 14 weeks 5 days   8.7 
16 Jayashree 30 23451 G3P2L2 12/6/11 19/3/12 13 weeks   6.7 
17 Thulasi 29 24350 G4P3L3 19/4/11 26/1/12 13 weeks 3 days  INEVITABLE ABORTION 4.6 
18 Annalakshmi 23 23170 G2P2L2 4/8/11 11/5/12 14 weeks   5.7 
19 Devi 21 23199 G2P2L2 13/5/11 20/2/12 12 weeks   9.4 
20 Deepa 22 22515 G2P2L2 17/6/11 26/3/12 12 weeks 2 days   5.4 
21 Amul 23 22511 G2P2L2 29/8/11 6/6/12 14 weeks MISSED ABORTION  6.7 
22 Saritha 24 27617 G2P2L2 15/7/11 22/4/12 13 weeks 3 days   3.6 
23 Sumathy 23 26511 G2P2L2 30/6/11 7/4/12 15 weeks 4 days   8.3 
24 Shoba 24 13979 G2P2L2 14/5/11 21/2/12 13 weeks   5.3 
25 Aseena 23 20989 G2P2L2 27/6/11 4/4/12 12 weeks   5.6 
26 Sangeetha 20 21343 G2P2L2 24/8/11 31/5/12 12 weeks 4 days   7.8 
27 Amutha 23 21347 G2P2L2 19/5/11 26/2/12 14 weeks 1 day MISSED ABORTION  3.5 
28 Mala 22 22901 G2P2L2 31/7/11 7/4/12 13 weeks   4.5 
29 Vijayalakshmi 21 23413 G2P2L2 14/6/11 21/3/12 12 weeks   5.4 
30 Meenakshi 23  G2P2L2 25/6/11 2/4/12 14weeks 3 days   7.5 
 
  
